Over 800,000 Australians are affected by retinal neurodegenerative diseases, such as glaucoma, diabetic retinopathy and age-related macular degeneration (AMD). Learn about our research uncovering new insights into the intricate workings of the retina, which could help prevent and develop new treatments for these diseases.

Our research investigates the role of mitochondria, the tiny ‘batteries’ which power our cells, in diseases of the eye and brain.

Learn more about nicotinamide (Vitamin B3) and glaucoma – what we know so far, how it may be protective against damage and the progress of our current study.

Learn about the potential of artificial intelligence to detect eye disease earlier,  identify those at risk of cardiovascular disease – and even compare your chronological age with your biological age.

Meet a multidisciplinary team who are using novel retinal imaging methods to detect people at risk of Alzheimer’s disease, as well as monitor disease progression and treatment responses.

View the detailed imagery that is used to uncover new markers of eye disease. These markers help to fast-track the discovery of new treatments and transform eye care to prevent irreversible vision loss.

Find out more about our research using the latest imaging technology to improve early detection and early treatment of eye cancer.

Our goal is to understand the cause of age-related macular degeneration (AMD) and how to treat it to preserve vision.

A next-generation bionic eye has been successfully implanted in seven patients with inherited retinal disease, giving them a ‘sense of sight’. Using a virtual reality headset, you’ll be able to simulate the artificial vision experienced by bionic eye recipients.

Our study aims to understand the natural progression of inherited retinal diseases (IRDs), like retinitis pigmentosa. Learn how we identify the genes involved in IRDs and how we find people with IRDs who may be eligible for upcoming clinical trials.

Adaptive technologies enable people with profound vision loss to use other senses. Experience how adaptive technology can support independent navigation and orientation for people with advanced stages of an inherited retinal disease (IRD).

Learn about CERA’s research into gene therapies that could slow down, or even halt, vision loss in patients with inherited retinal disease (IRD) and age-related macular degeneration (AMD).

Learn about our Genetic Engineering Research Unit’s use of nanotechnology, gene editing and other innovative technologies to create next generation gene therapies for inherited retinal diseases.

The team is investigating the use of technology to create longer lasting, less invasive treatments for a range of common eye diseases, including research to replace anti-VGEF injections with eye drops.

Our goal is to develop a safe and effective treatment to prevent scarring which causes glaucoma blindness. We’ll showcase our recent projects focusing on developing a new therapy to target scarring after glaucoma surgery and reduce potential risks and side effects.

Our research aims to develop a gene therapy to restore damaged photoreceptors. Under a microscope, you’ll see human retinal cells that we have generated in the lab using stem cell technologies.

The Corneal Research Unit develops solutions to prevent and reduce avoidable blindness due to corneal diseases. See researchers Dr Gink Yang and Dr Heather Machin demonstrate the intricacies involved in working with corneal tissue.

Meet the dedicated team who work with eye donors and their families to bring their gift of donation to waiting recipients, and find out how to become an eye donor yourself.

An expertly run clinical trial gathers the evidence needed to determine if a treatment is safe, effective and can make a difference for someone with eye disease.

Our Clinical Trial Research Centre is currently running 40 clinical trials, and has been part of large multi-national trials that have changed clinical practice.